These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
715 related articles for article (PubMed ID: 29972254)
1. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma. Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254 [TBL] [Abstract][Full Text] [Related]
2. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway. Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760 [TBL] [Abstract][Full Text] [Related]
3. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393 [TBL] [Abstract][Full Text] [Related]
4. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943 [TBL] [Abstract][Full Text] [Related]
5. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281 [TBL] [Abstract][Full Text] [Related]
6. Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma. Kim J; Jung KH; Yan HH; Cheon MJ; Kang S; Jin X; Park S; Oh MS; Hong SS BMC Complement Altern Med; 2018 May; 18(1):147. PubMed ID: 29739391 [TBL] [Abstract][Full Text] [Related]
7. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227 [TBL] [Abstract][Full Text] [Related]
8. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis. Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542 [TBL] [Abstract][Full Text] [Related]
9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
10. Artemisiae Iwayomogii Herba Inhibits Growth, Motility, and the PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma Cells. Kim J; Jung KH; Choi JG; Oh MS; Hong SS Planta Med; 2020 Jul; 86(10):717-727. PubMed ID: 32428938 [No Abstract] [Full Text] [Related]
11. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. Lu S; Gao Y; Huang X; Wang X Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538 [TBL] [Abstract][Full Text] [Related]
12. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin. Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391 [TBL] [Abstract][Full Text] [Related]
14. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway. Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938 [TBL] [Abstract][Full Text] [Related]
15. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710 [TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995 [TBL] [Abstract][Full Text] [Related]
17. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. Li GY; Jung KH; Lee H; Son MK; Seo J; Hong SW; Jeong Y; Hong S; Hong SS Cancer Lett; 2013 Feb; 329(1):59-67. PubMed ID: 23085493 [TBL] [Abstract][Full Text] [Related]
18. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167 [TBL] [Abstract][Full Text] [Related]
19. PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells. Wang FZ; Peng-Jiao ; Yang NN; Chuang-Yuan ; Zhao YL; Liu QQ; Fei HR; Zhang JG Toxicol Lett; 2013 Jul; 220(2):150-6. PubMed ID: 23639247 [TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]